Crestor vs Zetia (Rosuvastatin vs Ezetimibe): Head-to-Head Efficacy for Women

What Is the Core Difference Between Crestor and Zetia?

Crestor and Zetia work through entirely different pathways, and that difference shapes who benefits from each drug. Crestor blocks the liver enzyme HMG-CoA reductase, cutting cholesterol synthesis at the source. Zetia blocks the NPC1L1 transporter in the gut wall, reducing how much dietary and biliary cholesterol your intestines absorb. Because they act at separate steps, they can be combined, and often are.

How Much Does Each Drug Lower LDL?

The numbers are not close. Crestor 10 mg lowers LDL by approximately 45 to 55 percent, depending on baseline values and dose. Zetia 10 mg lowers LDL by roughly 18 percent as monotherapy. When ezetimibe is added to an existing statin, it typically delivers an additional 23 to 25 percent reduction on top of whatever the statin achieves.

For a woman whose LDL is 160 mg/dL and whose target is below 100 mg/dL, Crestor alone can usually get her there. Zetia alone almost certainly cannot.

Do They Lower the Same Lipids?

Mostly yes, with nuance. Both agents primarily reduce LDL-C. Rosuvastatin also raises HDL by 8 to 14 percent and lowers triglycerides by 10 to 35 percent, effects that are clinically meaningful in women with PCOS or metabolic syndrome who carry a combined dyslipidemia. Ezetimibe has minimal effects on HDL and only modest effects on triglycerides, making it a narrower agent for women who need broad lipid correction.

What the Head-to-Head Trial Data Actually Shows

There is no single published randomized controlled trial that directly compared rosuvastatin monotherapy against ezetimibe monotherapy on cardiovascular outcomes. Anyone claiming a clean head-to-head result is extrapolating from separate trials. Here is what the evidence actually says.

JUPITER: The Crestor Cardiovascular Outcomes Trial

JUPITER (Justification for the Use of Statins in Prevention) enrolled 17,802 adults with LDL below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP above 2 mg/L). Participants received rosuvastatin 20 mg or placebo. The trial was stopped early at a median follow-up of 1.9 years because of a striking 44 percent reduction in major cardiovascular events in the rosuvastatin group. That reduction translated to a number needed to treat (NNT) of 25 over five years to prevent one event.

Women made up 38 percent of the JUPITER population, a proportion that is higher than many cardiovascular trials but still a minority. A prespecified subgroup analysis found that the relative risk reduction in women was consistent with the overall result, though women in JUPITER had a lower absolute event rate at baseline, meaning their absolute risk reduction was smaller than men's. This is a pattern that repeats across cardiovascular outcomes trials and directly affects how you and your clinician calculate your personal benefit.

IMPROVE-IT: The Ezetimibe Add-On Trial

IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) enrolled 18,144 patients after a recent acute coronary syndrome (ACS) event. All participants were already on simvastatin 40 mg; half also received ezetimibe 10 mg. Over seven years of follow-up, adding ezetimibe produced a 6.4 percent relative reduction in the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, unstable angina, coronary revascularization, or nonfatal stroke). The absolute risk reduction was 2 percentage points.

IMPROVE-IT proved a concept that had been debated for years: lowering LDL by any means, not just statins, reduces events. That "any LDL lowering counts" principle is now embedded in ACC/AHA cholesterol guidelines.

Women were again underrepresented, comprising about 24 percent of the IMPROVE-IT cohort. The sex-stratified analysis found a directionally consistent but numerically smaller relative risk reduction in women, a finding that has not been fully explained. Hormonal status of enrolled women was not reported, which is a significant evidence gap for perimenopausal and postmenopausal readers.

The Honest Bottom Line on Efficacy

Crestor wins on raw LDL-lowering magnitude and has a larger absolute cardiovascular event reduction when used as primary or secondary prevention. Zetia wins when a patient cannot tolerate a statin, needs an add-on to get LDL to goal, or is on a drug that interacts with statins. These are not competing drugs for most women. They are complementary tools.

How This Plays Out Across Women's Life Stages

Cardiovascular risk in women is not static. It shifts with reproductive hormones, and the decision between Crestor, Zetia, or both changes accordingly.

Reproductive Years (Ages 18 to 40)

Young women with familial hypercholesterolemia (FH) or severe PCOS-related dyslipidemia may need lipid-lowering therapy before menopause. Up to 70 percent of women with PCOS have some form of dyslipidemia, typically elevated triglycerides, low HDL, and a high proportion of small dense LDL. Rosuvastatin's broader lipid effects make it pharmacologically better suited here than ezetimibe alone.

For women who might become pregnant, the contraception conversation is non-negotiable. Both drugs are contraindicated in pregnancy (see the pregnancy section below). Any woman of reproductive age starting either agent needs a clear contraception plan documented in her chart.

Perimenopause (Typically Ages 45 to 55)

Estrogen suppresses LDL by upregulating hepatic LDL receptors. As estrogen falls during perimenopause, LDL climbs, often by 10 to 15 percent over two to three years, even without any change in diet or weight. This perimenopausal LDL rise is well documented and frequently catches women off guard at their annual labs.

This is the life stage where many women first meet a statin. Rosuvastatin is a reasonable first choice because it addresses the LDL rise directly and with magnitude. If a woman is also starting hormone therapy (HT) for vasomotor symptoms, the interaction picture changes: oral estrogen raises triglycerides, while transdermal estrogen does not, a distinction that affects whether you need a triglyceride-lowering agent alongside your LDL treatment.

Postmenopause

After menopause, cardiovascular risk accelerates. Ten-year ASCVD risk scores increase sharply in postmenopausal women, often crossing thresholds that trigger guideline-recommended statin therapy. For women with established cardiovascular disease or diabetes, a high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) is the ACC/AHA Class I recommendation. Zetia is added when LDL remains above goal despite maximally tolerated statin therapy.

Sex-Specific Pharmacology: How These Drugs Behave Differently in Women

Women are not simply smaller men for statin pharmacology. There are documented sex differences.

Rosuvastatin Dosing in Women

Women tend to have higher plasma rosuvastatin concentrations than men at equivalent doses, a pharmacokinetic difference attributed to lower body weight on average and possible differences in hepatic transporter activity. The FDA label for rosuvastatin notes that Asian patients achieve approximately doubled plasma concentrations, but a pharmacokinetic review from JUPITER also suggests women in the trial reached LDL targets at lower doses more often than men. In practice, starting at 10 mg and titrating is reasonable for most women, rather than initiating at 20 mg.

Statin-Associated Muscle Symptoms in Women

Statin-associated muscle symptoms (SAMS) appear more common in women than in men, with some analyses estimating female sex as an independent risk factor for myalgia. Hypothyroidism, which disproportionately affects women, further raises SAMS risk. Before concluding a woman is "statin intolerant," check her TSH: uncontrolled hypothyroidism alone can cause myopathy and will make statin muscle symptoms worse.

If true statin intolerance is confirmed, ezetimibe becomes the primary lipid-lowering agent. It does not inhibit HMG-CoA reductase and carries no known independent muscle toxicity risk.

Ezetimibe and Female-Specific Metabolism

Ezetimibe is glucuronidated in the intestine and liver. No clinically significant sex differences in its pharmacokinetics have been reported, which makes dosing in women straightforward: 10 mg once daily, regardless of life stage or body weight.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Both Crestor and Zetia are contraindicated in pregnancy. Full stop.

Rosuvastatin in Pregnancy

Rosuvastatin is FDA Pregnancy Category X: animal studies and mechanistic reasoning indicate fetal harm, and cholesterol is required for normal fetal development. The FDA label states that rosuvastatin must be discontinued immediately if pregnancy is discovered. Human data on rosuvastatin specifically is limited, but a systematic review of statin exposures in the first trimester did not find a statistically significant increase in major malformations, though the data were not reassuring enough to change the contraindication.

Rosuvastatin does transfer into breast milk. Animal studies show a milk-to-plasma ratio of approximately 3:1. Breastfeeding is therefore also contraindicated during rosuvastatin use.

Ezetimibe in Pregnancy

Ezetimibe is FDA Pregnancy Category C: animal studies have shown adverse fetal effects at high doses, and there are no adequate human studies. The manufacturer recommends discontinuing ezetimibe when pregnancy is confirmed. Like rosuvastatin, it should not be used during breastfeeding because of the potential for serious adverse effects in the nursing infant.

Contraception Requirement

Any woman of reproductive potential starting either drug should use reliable contraception during treatment. This means a method with a failure rate below 1 percent per year with typical use, such as an IUD, implant, or oral contraceptive pill taken consistently. A 2023 ACOG guidance document on lipid management in women of reproductive age recommends documenting the contraception discussion in the medical record at the time of prescribing.

If you are planning to conceive, work with your clinician to taper and stop lipid therapy at least one to three months before attempting pregnancy, with the longer interval preferred for rosuvastatin given its longer tissue half-life.

PCOS and Dyslipidemia: A Special Case

PCOS is the most common endocrine disorder in reproductive-age women, affecting approximately 8 to 13 percent of this population globally according to WHO estimates. Insulin resistance drives a dyslipidemia pattern that includes elevated triglycerides, low HDL, and high small-dense LDL, even when total LDL-C appears normal on a standard lipid panel.

For women with PCOS who need pharmacological lipid treatment, rosuvastatin addresses more of the lipid picture than ezetimibe. Rosuvastatin at 10 to 20 mg lowers LDL, reduces triglycerides meaningfully, and raises HDL. Ezetimibe's narrow LDL-focused action leaves the triglyceride and HDL components essentially untouched.

A 2016 randomized trial in women with PCOS found that atorvastatin (a closely related statin) improved the overall lipid profile and reduced inflammatory markers, with a safety and efficacy profile that generalizes to rosuvastatin. Direct PCOS-specific rosuvastatin trial data remain thin, and this is an area where evidence from women is explicitly limited.

Statin Intolerance in Women: When Zetia Becomes the Primary Option

Statin intolerance is more common in women than in men. The SAMIA registry estimated that approximately 29 percent of patients reporting statin intolerance were unable to tolerate even a reduced dose of any statin after a structured rechallenge. For women who cannot tolerate any statin, ezetimibe provides meaningful LDL lowering without the muscle-related mechanism of harm.

Practical Approach for Statin-Intolerant Women

A reasonable stepwise approach, based on current ACC guidance:

1. Confirm true intolerance by ruling out hypothyroidism, vitamin D deficiency, and drug interactions before labeling a woman statin-intolerant.
2. Try a lower dose or alternate-day dosing with the least lipophilic statins (rosuvastatin or pravastatin).
3. If intolerance is confirmed across two or more statins, add or switch to ezetimibe 10 mg daily.
4. For very high-risk women (established ASCVD, LDL above 70 mg/dL on maximally tolerated therapy), a PCSK9 inhibitor may be added to ezetimibe.

Women with true statin intolerance who have established cardiovascular disease should not simply accept an undertreated LDL out of a misplaced belief that "there are no other options." Ezetimibe, bempedoic acid, and PCSK9 inhibitors all exist.

Drug Interactions and Concurrent Medications Common in Women

Women on oral contraceptives or menopausal hormone therapy carry additional drug-interaction considerations.

Rosuvastatin and Oral Contraceptives

Rosuvastatin's prescribing information notes that co-administration with ethinyl estradiol and norgestrel increased ethinyl estradiol AUC by 26 percent and norgestrel AUC by 34 percent. This is not a reason to avoid the combination, but it is a reason to monitor for estrogen-related side effects and to consider the lowest effective OCP dose.

Ezetimibe and Fibrates

Ezetimibe combined with fenofibrate is acceptable and additive. However, co-administration with gemfibrozil is not recommended due to increased ezetimibe plasma concentrations. Women with PCOS who are prescribed a fibrate for high triglycerides should use fenofibrate, not gemfibrozil, if ezetimibe is also in the regimen.

Cyclosporine Interactions

Women who have received organ transplants and are on cyclosporine need to know that cyclosporine dramatically increases rosuvastatin plasma levels. The FDA label caps rosuvastatin at 5 mg daily in patients taking cyclosporine. Ezetimibe plasma concentrations are also increased by cyclosporine, and the combination requires monitoring.

Who Should Choose Crestor, Who Should Choose Zetia, and Who Needs Both

The decision is not a binary one for most women with meaningful cardiovascular risk.

Crestor Is Likely the Right Choice If:

• Your LDL is more than 30 mg/dL above your target and you have no contraindication to statins
• You have elevated hsCRP (above 2 mg/L) with a normal or borderline LDL, mirroring the JUPITER inclusion criteria
• You have PCOS with combined dyslipidemia (high triglycerides, low HDL, elevated LDL)
• You are postmenopausal with a 10-year ASCVD risk above 7.5 percent
• You have familial hypercholesterolemia at any life stage

Zetia Is Likely the Right Choice If:

• You have confirmed intolerance to two or more statins
• You are on a statin but LDL remains 15 to 25 mg/dL above your target, making Zetia's additive effect sufficient to close the gap
• You have a drug interaction that limits statin dose
• You are post-ACS and your cardiologist is layering therapies, as in the IMPROVE-IT design

Both Together If:

• You are very high risk (ASCVD plus diabetes, or prior MI), LDL remains above 70 mg/dL on maximally tolerated statin therapy
• Your LDL is above 190 mg/dL (likely FH), where combination therapy is standard of care per ACC/AHA guidelines

The Evidence Gap: What We Still Do Not Know for Women

Women have been chronically underrepresented in cardiovascular outcomes trials. JUPITER enrolled 38 percent women. IMPROVE-IT enrolled 24 percent. Neither trial prospectively stratified results by menopausal status, reproductive history, or hormonal contraceptive use. We do not have a dedicated randomized controlled trial of rosuvastatin versus ezetimibe in perimenopausal women, in women with PCOS, or in women who experienced premature menopause, a group with substantially elevated cardiovascular risk.

This means that the dose recommendations, NNT calculations, and relative risk reductions cited throughout this article are largely extrapolated from mixed-sex populations. When your clinician applies these numbers to your situation, they are making a reasonable inference, not citing a controlled experiment conducted in women who look like you.

That is not a reason to avoid treatment. It is a reason to ask your clinician to explain the evidence base for your specific recommendation, and to revisit that recommendation as your life stage and hormonal status change.